/Investor DB

DeepWork Capital — 2020 Investments

2 investments dated 2020 · listed companies and verified rows first · show all

Aegle Therapeuticsaegletherapeutics.comJan 2020

Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells.

BiotechHealthtechMedical DevicesWoburn, US

Shelley A. Hartman(Co-founder & CEO)inEvangelos V. Badiavas(Founder & Chief Scientific Officer)Heidi Kempinski(Chief Operational Officer)inKathleen Murphy(Head of Clinical Operations)Robert Williamson, Jr.(Executive Officer, Director)Robert Ryan(Director)

Co-investorsDEFTA PartnersNew World AngelsOcean Azul Partners

eterna teareternatear.cominNov 2020

Eternatear develops diagnostic and therapeutic products for dry eye disease, particularly targeting Meibomian Gland Dysfunction.

BiotechHealthtechMedical DevicesRaleigh, US

Timothy Willis(Chief Executive Officer & Chairman of the Board)Kent Geer(Chief Financial Officer & Secretary)Tim Willis(CEO, Chairman of the Board)Ralph Stone(Chief Technology Officer)Joe Huber(Chief Operating Officer)Diethart Reichardt(Chief Marketing Officer & Board Director)

Co-investorsArieal Southeast Angel PartnersCharlotte Angel FundDuke Capital PartnersKleinmuntz AssociatesBand of AngelsCarolina Angel Network+2 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.